A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Summary

The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting side effects from it. Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) will take Maribavir tablets two times a day for 8 weeks in this study. During the study, participants will visit their study clinic 18 times as a maximum.

Timeline

Start

2022-01-18

Primary completion

2023-06-27

Completion

2023-06-27

Publications

• Kanda Y, Takenaka K, Tanabe T, Omoto K, Kamimura K, Kudou K, Kaneko M. Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study. Int J Hematol. 2026 Jun 12. doi: 10.1007/s12185-026-04220-3. Online ahead of print.

Drugs

Indications